ES2252554T3 - Pirimidotriacinas como inhibidores de fosfatasa. - Google Patents

Pirimidotriacinas como inhibidores de fosfatasa.

Info

Publication number
ES2252554T3
ES2252554T3 ES02805774T ES02805774T ES2252554T3 ES 2252554 T3 ES2252554 T3 ES 2252554T3 ES 02805774 T ES02805774 T ES 02805774T ES 02805774 T ES02805774 T ES 02805774T ES 2252554 T3 ES2252554 T3 ES 2252554T3
Authority
ES
Spain
Prior art keywords
ylmethyl
diamine
triazine
pyrimido
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02805774T
Other languages
English (en)
Spanish (es)
Inventor
Kevin Richard Guertin
Lina Quattrocchio Setti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2252554T3 publication Critical patent/ES2252554T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
ES02805774T 2001-12-27 2002-12-27 Pirimidotriacinas como inhibidores de fosfatasa. Expired - Lifetime ES2252554T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34393701P 2001-12-27 2001-12-27
US343937P 2001-12-27
US39911002P 2002-07-26 2002-07-26
US399110P 2002-07-26

Publications (1)

Publication Number Publication Date
ES2252554T3 true ES2252554T3 (es) 2006-05-16

Family

ID=26993696

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02805774T Expired - Lifetime ES2252554T3 (es) 2001-12-27 2002-12-27 Pirimidotriacinas como inhibidores de fosfatasa.

Country Status (19)

Country Link
US (1) US6642381B2 (Direct)
EP (1) EP1467996B1 (Direct)
JP (1) JP4188839B2 (Direct)
KR (1) KR100601769B1 (Direct)
CN (1) CN100402530C (Direct)
AT (1) ATE311388T1 (Direct)
AU (1) AU2002367190B2 (Direct)
BR (1) BR0215395A (Direct)
CA (1) CA2471265C (Direct)
DE (1) DE60207759T2 (Direct)
ES (1) ES2252554T3 (Direct)
JO (1) JO2242B1 (Direct)
MX (1) MXPA04006266A (Direct)
PA (1) PA8562901A1 (Direct)
PE (1) PE20030896A1 (Direct)
PL (1) PL371180A1 (Direct)
TW (1) TW200306313A (Direct)
UY (1) UY27606A1 (Direct)
WO (1) WO2003055883A1 (Direct)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696231B2 (en) * 2001-10-30 2010-04-13 Laboratoires Serono Sa Oxindole hydrazide modulators of protein tyrosine phosphatases (PTPs)
ATE427951T1 (de) 2002-11-18 2009-04-15 Hoffmann La Roche Diazinopyrimidine und ihre verwendung als proteinkinaseinhibitoren
AU2004210711B2 (en) * 2003-02-12 2010-07-08 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
US20040186151A1 (en) * 2003-02-12 2004-09-23 Mjalli Adnan M.M. Substituted azole derivatives as therapeutic agents
JP4898458B2 (ja) * 2004-02-12 2012-03-14 トランス テック ファーマ,インコーポレイテッド 置換アゾール誘導体、組成物及び使用方法
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
NZ569329A (en) * 2006-01-30 2011-09-30 Transtech Pharma Inc Substituted imidazole derivatives and their use as PTPase inhibitors
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2009256157B2 (en) 2008-06-04 2014-12-18 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
WO2010083645A1 (en) * 2009-01-21 2010-07-29 Shanghai Targetdrug Co., Ltd PYRIMIDO[5,4-e][1,2,4]TRIAZINES AND USES THEREOF
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9486433B2 (en) 2012-10-12 2016-11-08 Mochida Pharmaceuticals Co. Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
KR20150127599A (ko) 2013-03-15 2015-11-17 모치다 세이야쿠 가부시키가이샤 비알코올성 지방간염을 치료하기 위한 조성물 및 방법
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
AU2014274812B2 (en) 2013-06-05 2018-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase C, method of making and using same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194410B1 (en) * 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
GB0022079D0 (en) 2000-09-08 2000-10-25 Inst Of Molecul & Cell Biology Novel protein tyrosine phosphatase inhibitor

Also Published As

Publication number Publication date
DE60207759T2 (de) 2006-08-03
JP4188839B2 (ja) 2008-12-03
UY27606A1 (es) 2003-06-30
TW200306313A (en) 2003-11-16
AU2002367190A1 (en) 2003-07-15
ATE311388T1 (de) 2005-12-15
MXPA04006266A (es) 2004-09-27
KR20040068981A (ko) 2004-08-02
AU2002367190B2 (en) 2006-10-05
JO2242B1 (en) 2004-10-07
BR0215395A (pt) 2004-12-07
DE60207759D1 (de) 2006-01-05
KR100601769B1 (ko) 2006-07-19
PA8562901A1 (es) 2003-07-28
CA2471265C (en) 2010-02-09
EP1467996B1 (en) 2005-11-30
PE20030896A1 (es) 2003-11-05
US6642381B2 (en) 2003-11-04
PL371180A1 (en) 2005-06-13
WO2003055883A1 (en) 2003-07-10
CN100402530C (zh) 2008-07-16
JP2005517677A (ja) 2005-06-16
EP1467996A1 (en) 2004-10-20
CN1610683A (zh) 2005-04-27
US20030153756A1 (en) 2003-08-14
CA2471265A1 (en) 2003-07-10

Similar Documents

Publication Publication Date Title
ES2252554T3 (es) Pirimidotriacinas como inhibidores de fosfatasa.
ES2336603T3 (es) Compuestos de pirido(2,3-d)pirimidina-2,4-diamina como inhibidores de ptp1b.
ES2315566T3 (es) Tiazolidin-4-onas para inhibir proteinas hyak3.
EP2010505B1 (en) Heterocyclic compounds and uses thereof in the treatment of sexual disorders
ES2253881T3 (es) Inhibidores de quinasa dependiente de ciclinas.
ES2709034T3 (es) Pirimido[4,5-b]quinolina-4,5 (3h,10h)-dionas como supresores de mutaciones sin sentido
ME02064B (me) Derivati kvinazolin-4(3h)-ona korisceni kao inhibitori pi3 kinaze
US20150320759A1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
BRPI0718029A2 (pt) Derivados de imidazo(1,2-b)piridazina e pirazolo(1,5-a)pirimidina e seu uso como inibidores da proteína cinase
BR112017005111B1 (pt) Compostos análogos de nucleotídeo acíclico, composição farmacêutica contendo tais compostos, e usos da composição no tratamento de uma infecção por papilomavírus
US20190359638A1 (en) Nucleotide Analogs
IE910994A1 (en) Multi-functional pharmaceutical compounds and methods of use
US6197775B1 (en) Phosphonate nucleotide derivatives
KR20190025545A (ko) 특정 단백질 키나제 억제제
AU2003238915A1 (en) (halo-benzo carbonyl)heterobicyclic p38 kinase inhibiting agents
US20210070742A1 (en) Sulfoximine, sulfonimidamide, sulfondiimine and diimidosulfonamide compounds as inhibitors of indoleamine 2,3-dioxygenase
US20240376076A1 (en) Inhibitors targeting ubiquitin specific protease 7 (usp7)
US20210395252A1 (en) 3,9-diazaspiro[5,5]undecane compound as flt3 and axl inhibitors
US20040110775A1 (en) Cyclin dependent kinase inhibiting purine derivatives
US10800785B2 (en) Substituted pyrrolo[2,3-d]pyridazin-4-ones and pyrazolo[3,4-d]pyridazin-4-ones as protein kinase inhibitors
ES2312968T3 (es) Compuestos novedosos.
WO2015014283A1 (zh) 蛋白酪氨酸激酶抑制剂及其应用
RU2289583C2 (ru) Пиримидотриазины, способ их получения, фармацевтическая композиция на их основе и применение
CN1668288B (zh) 具有抗寄生虫活性的化合物和含有它们的药物
BG106811A (bg) Производни на захарин като орални активни инхибитори на еластаза